Stem cell-based tissue engineering in veterinary orthopaedics

Brehm, Walter; Burk, Janina; Delling, Uta; Gittel, Claudia; Ribitsch, Iris

doi:10.1007/s00441-011-1316-1

Cited by 27 publications

(18 citation statements)

References 114 publications

(140 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 Recently, various applications of tissue engineering have been reported in veterinary medicine. 2,3 One of the main difficulties in tissue engineering is that the vascularization of the engineered tissues is inevitable. Previous studies 4,5 reveal that vascularization in engineered tissues with mature endothelial cells improves blood perfusion, cell viability, and survival of the tissues after transplantation.…”

mentioning

confidence: 99%

Differentiation of canine adipose tissue–derived mesenchymal stem cells towards endothelial progenitor cells

Kang¹,

Lee²,

Kweon³

et al. 2014

ajvr

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Differentiation of canine adipose tissue–derived mesenchymal stem cells towards endothelial progenitor cells

Kang¹,

Lee²,

Kweon³

et al. 2014

ajvr

View full text Add to dashboard Cite

show abstract

“…The positive and negative pre-clinical results are to be published and made available to patients and public. These TEMPs can be tested in various general veterinary medical hospitals with due animal ethics approvals as pre-clinical results and an opportunity to upgrade the veterinary clinical medicine [35] . Pre-clinical studies provides the basic toxicity profiles, enables to identify the active dose levels, adverse events, supports trial eligibility criteria, and enables to identify the critical clinical parameters, risk benefit criteria.…”

Section: Regulations For Innovative Tempsmentioning

confidence: 99%

Clinical Translation of Tissue Engineered Medicinal Products

Kn¹,

Gottipamula²,

Internationals³

2016

JSRB

View full text Add to dashboard Cite

Tissue Engineering is a rapidly growing field with novel scientific concepts, new technological methods, and evolving regulatory policies for clinical translation. Most of the current basic regulations are taken from the pharma, bio-pharma, cell therapy with little modifications, and new inclusion for development of regulatory frame work for advanced therapeutic products. We propose to highlight the important concepts in the regulatory development for tissue engineered based medicinal products (TEMPs) without any compromise on Quality, safety and efficacy. Moreover, these evolving regulations should facilitate clinical transition to help large numbers of patients on conditionally or case-by-case basis, and accelerate the submission of on-line real-time safety and efficacy parameters. This review describes general regulations and its scientific concepts; specifically in the context of clinical translation for TEMPs. Importantly, this review highlights the need of regulatory development and support for sustenance of small and medium sized organizations without any compromise on safety and efficacy of the products. Furthermore, current clinical regulatory translational challenges and opportunities to articulate risk-benefit approaches by accessing its potential strength, efficacy or availability of standard therapy, safety of new product and its relevance's with TEMPs are discussed. native to reconstructive bio-surgeries. These innovative therapies are made available to potential patients in timely manner. Figure 1: General process map and characterization of TEMPs: Overview of process from cell sourcing to IMP Production and intermediate bank/ biomaterial qualification steps. Critical components for characterization are at six corners of hexagonal i.e., identity, potency, purity, safety, stability and viability demonstrate the quality and efficacy of process and product. Related techniques for each critical characteristics were displayed in box. Abbreviations: ID-Infectious diseases; IMP-Investigational Medicinal Products; MCB-Master cell bank; TEMP-Tissue Engineered medicinal products; WCB-Working cell bank.The TEMPs are combinations of cells and regenerative matrices, which involves the bioengineering approaches to engraft the biomaterial and cells to retain the tissue-level functions. The unique natures of the products are being convergent to traditional regulatory process for safety and efficacy evaluations. Understanding the regulatory requirements and meeting to reach the evolving regulatory expectation of TEMP during the transition period is even more difficult for start-up entrepreneurs or small companies in early stage of clinical trials. Further vast requirements on product development and pre-clinical data within defined time frame makes developers to evolve various adaptation strategies to complete clinical transitional phase of TEMPs. On the other hand, significant reduction in development time for acellular TEMP for tropical applications were expected [4,5] . Further, cell secretome of cell culture co...

show abstract

“…In horses, a few preliminary experiments have been performed in which a pastern joint arthrodesis was supported by a combined therapy of stem cells and a bone replacement material, resulting in an adequate development of bone fusion (Brehm et al 2012). However, controlled clinical studies on the application of MSC in bone regeneration in horses have not yet been reported.…”

Section: Months No Significant Effectmentioning

confidence: 99%

Mesenchymal stem cell therapy in horses: useful beyond orthopedic injuries?

Schauwer

Walle

Soom

et al. 2013

Veterinary Quarterly

View full text Add to dashboard Cite

In the past decade, mesenchymal stem cells (MSC) have received much attention in equine veterinary medicine. The first therapeutic use of equine MSC was reported in 2003. Since then, the clinical application of MSC has been exploding with thousands of horses now treated worldwide. At present, MSC are mainly used in veterinary medicine to treat musculoskeletal diseases based on their ability to differentiate into various tissues of mesodermal origin. This is in marked contrast to human medicine, where MSC therapies are primarily focused on immune-mediated, inflammatory, and ischemic diseases. In this review, both orthopedic as well as non-orthopedic clinical applications of equine MSC are discussed. A brief overview is provided on the potential of MSC for non-orthopedic injuries with emphasis on those diseases, which occur in both humans and horses.

show abstract

Stem cell-based tissue engineering in veterinary orthopaedics

Cited by 27 publications

References 114 publications

Differentiation of canine adipose tissue–derived mesenchymal stem cells towards endothelial progenitor cells

Differentiation of canine adipose tissue–derived mesenchymal stem cells towards endothelial progenitor cells

Clinical Translation of Tissue Engineered Medicinal Products

Mesenchymal stem cell therapy in horses: useful beyond orthopedic injuries?

Contact Info

Product

Resources

About